Health Economics Research Topics
— NHS, Medicare & Policy
A comprehensive, expert guide to health economics research topics for undergraduate, postgraduate, and doctoral students — covering NHS funding and sustainability, Medicare and Medicaid reform, universal health coverage, pharmaceutical pricing, health inequalities, cost-effectiveness analysis, mental health economics, long-term care financing, and global health system comparisons. Whether you are selecting a dissertation topic, designing an empirical study, or navigating the theoretical landscape of healthcare markets, this guide gives you the conceptual depth and practical specificity to produce research that matters.
📋 Need expert help with your health economics research paper or essay? Our specialists are ready.
Get Research Help →What Is Health Economics — and Why Does It Matter for Research?
Health economics is the branch of applied economics that studies how scarce resources are allocated in the production and consumption of healthcare — examining how individuals, providers, insurers, and governments make decisions under uncertainty and resource constraints, how healthcare markets differ from conventional markets, how health systems are financed and organised, and what the efficiency and equity consequences of different policy choices are. It combines microeconomic theory of individual behaviour with macroeconomic analysis of health system financing, and deploys a distinctive evaluative toolkit — including cost-effectiveness analysis and health technology assessment — to guide coverage decisions and resource allocation in systems operating under perpetual budgetary pressure.
Few fields sit as close to the intersection of intellectual rigour and urgent real-world consequence as health economics. The question of how to allocate finite resources across competing health needs — who gets access to an expensive cancer drug, whether a new mental health programme represents good value for public money, whether a government should fund primary prevention or acute care — is simultaneously a technical economic problem and a deeply moral one. Health economics takes seriously both dimensions: it applies the analytical tools of economics to generate precise, evidence-based answers, while remaining engaged with the equity concerns and value judgements that no technical analysis can fully resolve.
The field emerged as a distinct discipline largely through Kenneth Arrow’s landmark 1963 paper “Uncertainty and the Welfare Economics of Medical Care,” which systematically identified the features that make healthcare markets fundamentally different from standard commodity markets — and therefore likely to fail without significant institutional intervention. Arrow identified asymmetric information between patients and providers, the unpredictability of illness and its associated demand for care, the complex role of insurance in reshaping incentives, and the difficulty of conventional consumer sovereignty in a market where the product is health itself. These insights remain the theoretical foundation of health economics half a century later, generating an ongoing research programme that examines when and how markets, regulation, and public provision can best serve the goal of a healthy population.
The significance of health economics research extends from the most local to the most global scale. At the individual level, it informs the clinical guidelines that shape treatment decisions, the formulary policies that determine which drugs are available, and the insurance designs that determine whether care is financially accessible. At the system level, it generates the evidence base for NHS reform in England, Medicare restructuring in the United States, and universal health coverage expansion in low- and middle-income countries. At the global level, it shapes the allocation of development assistance for health, the design of pandemic preparedness infrastructure, and the negotiations over intellectual property rights that determine whether life-saving medicines are accessible in poor countries. For students writing in this field, our research paper writing specialists and economics homework help team offer expert support across all research areas covered in this guide.
How to Use This Guide
This guide is organised thematically across ten major health economics research areas. Each section introduces the theoretical landscape, identifies the key research questions driving current scholarship, and maps specific researchable topic ideas at multiple levels of complexity — from undergraduate seminar papers to doctoral dissertations. The topics span the NHS and UK health policy, the US Medicare and Medicaid system, comparative international health systems, and the methodological frameworks (cost-effectiveness analysis, health technology assessment, inequality measurement) that underpin empirical work across all these contexts. For expert support at any stage of your research, Smart Academic Writing provides specialist assistance from initial topic selection through final submission.
The Core Theoretical Concepts Every Health Economics Researcher Must Know
Before exploring specific research areas, several theoretical concepts recur throughout health economics and form the analytical vocabulary of the field. Moral hazard describes the tendency for insurance to increase healthcare utilisation by reducing the marginal cost of care to the insured individual — a phenomenon documented extensively since the RAND Health Insurance Experiment of the 1970s and with profound implications for insurance design, copayment policy, and healthcare spending trajectories. Adverse selection describes the tendency for insurance markets to attract disproportionate numbers of high-risk individuals, potentially leading to market unravelling — the theoretical basis for mandatory insurance requirements and community rating regulations. Supplier-induced demand refers to the capacity of healthcare providers, due to information asymmetry and agency relationships with patients, to generate demand for services beyond what a fully informed patient would independently choose — with implications for how provider payment systems should be designed.
The equity-efficiency trade-off is perhaps the most persistent conceptual tension in health economics research: policies that maximise aggregate health gain (efficiency) do not necessarily distribute that gain equitably across the population, and policies that prioritise equity may sacrifice some aggregate benefit. Understanding how different health systems navigate this trade-off — and whether it is as stark as often assumed — motivates a substantial body of comparative health systems research. Quality-adjusted life years (QALYs) are the standard unit of health benefit used in economic evaluation — a composite measure that weights life years by a quality-of-life score between zero and one, allowing comparisons across conditions and interventions. Their use by bodies like NICE in England and CADTH in Canada to determine coverage and reimbursement makes them one of the most consequential and contested constructs in health policy, and understanding their properties, limitations, and alternatives is essential background for research in cost-effectiveness and health technology assessment. For broader academic writing support across economics and health policy, see our essay writing services and public health assignment help.
NHS Funding, Sustainability, and Reform — Research at the Heart of British Health Policy
The National Health Service is simultaneously one of the most studied health systems in the world and one of the most urgently in need of fresh economic analysis. Founded in 1948 on the principles of universality, comprehensiveness, and free provision at the point of use, the NHS has spent its entire history navigating the tension between those founding commitments and the fiscal reality of finite public resources and continuously expanding medical possibilities. For health economics researchers, it represents an unparalleled natural laboratory — a system large enough to generate statistically powerful evidence, old enough to have historical data spanning multiple decades and reform cycles, and institutionally complex enough to support research questions ranging from micro-level provider incentives to macro-level system design.
The central challenge facing NHS research in the 2020s is a funding and demand gap of historically unprecedented proportions. A combination of post-pandemic backlogs, demographic pressures from an ageing population, rising multimorbidity, workforce shortages, and the long-run consequences of austerity-driven funding constraints between 2010 and 2019 has produced a system operating well below its potential performance benchmarks. Understanding the economic dimensions of this crisis — its drivers, its distributional consequences, and the comparative evidence on what reforms might address it — is one of the most pressing research agendas in UK health policy.
The Productivity Paradox in NHS Secondary Care
Despite sustained investment in information technology and management reform, NHS hospital productivity has grown more slowly than comparable healthcare systems. Research into the economic drivers of this productivity gap — and what international evidence suggests about effective interventions — remains a high-priority area for both academic and policy-oriented health economics.
NHS Waiting Times and Health Outcomes: Quantifying the Cost of Delay
Prolonged waiting times for elective procedures represent both a welfare cost (time in pain or disability while awaiting treatment) and a clinical cost (deterioration in conditions that are sensitive to treatment timing). Estimating these costs empirically, and evaluating alternative strategies for reducing them, connects to broader debates about how NHS resources should be prioritised.
GP Gatekeeping and the Economics of Primary Care Access
The NHS primary care model relies on GPs as the gatekeepers to secondary care — a design intended to promote appropriate utilisation and cost efficiency. As GP access deteriorates and patients increasingly bypass primary care through emergency departments, the economic consequences of this structural shift require rigorous analysis.
Integrated Care Systems: Economic Theory and Early Evidence
The 2022 Health and Care Act restructured NHS commissioning around Integrated Care Systems (ICSs), with the ambition of reducing fragmentation across primary, secondary, and social care. The economic rationale for integration — and the early evidence on whether it improves outcomes or reduces costs — represents a live and consequential research question.
NHS Workforce Economics: Supply, Demand, and International Migration
The NHS is structurally dependent on internationally trained health workers — particularly nurses and doctors from South Asia, Africa, and the EU. The economic analysis of this dependence — its causes, its ethical dimensions, and its implications for workforce planning — raises questions at the intersection of health labour markets and global health equity.
The Cost of Social Care Underfunding to NHS Acute Services
Inadequate social care provision generates NHS costs through delayed hospital discharges, emergency admissions for preventable deterioration, and unplanned acute care for people who could be managed in community settings. Quantifying this cross-boundary fiscal transfer is both methodologically challenging and politically consequential.
The NHS is not a national health service — it is a national sickness service. The investment in health that most powerfully determines outcomes happens outside hospitals, in housing, education, and the conditions of daily life that economics helps us measure but policy too rarely addresses.
— Adapted from Sir Michael Marmot, Health Equity in England (2020)Payment Systems and Provider Incentives in the NHS
How NHS providers are paid is one of the most consequential determinants of what they do and how efficiently they do it. The shift from block contracts to activity-based payment (Payment by Results, later National Tariff Payment System) in the 2000s was motivated by the economic logic that fee-for-service payment rewards activity and thereby reduces waiting times and improves responsiveness. The evidence on whether this ambition was realised — and at what cost in terms of cream-skimming, gaming, and quality trade-offs — has generated a substantial empirical literature that continues to evolve as NHS payment policy is reformed. Research questions in this area include the effects of specific tariff structures on treatment mix, the relationship between payment generosity and quality, the consequences of moving from individual provider payment to population-based capitation under ICSs, and the comparative evidence from other countries’ experiments with value-based payment systems that attempt to pay for outcomes rather than activity.
The independent sector treatment centre (ISTC) programme and subsequent extensions of patient choice and provider competition in the NHS offer a particularly rich natural experiment for health economics research. The economic theory of competition in healthcare — developed by Martin Gaynor, Carol Propper, and colleagues — predicts that competition on quality will improve outcomes where patients are price-insensitive (as in the NHS, where care is free at the point of use), but the empirical evidence has been mixed, with results sensitive to the specific market structure, the outcome measured, and the time period examined. For students researching NHS market reforms, our economics assignment specialists and literature review writing team can provide comprehensive support at every stage of the analysis.
Medicare, Medicaid, and US Health System Reform — The World’s Most Studied Puzzle
The United States healthcare system is the most expensive in the world by nearly every measure — spending more per capita than any comparable nation while producing health outcomes that rank poorly among high-income countries on most indicators. This combination makes it simultaneously the most important and the most frustrating object of health economics research: a vast natural experiment in the consequences of organising healthcare primarily through private insurance markets, with public programmes — Medicare for the elderly and disabled, Medicaid for low-income populations — operating alongside a fragmented system of employer-sponsored insurance, individual market coverage, and uninsurance.
Medicare, established in 1965 alongside Medicaid as part of President Johnson’s Great Society programme, covers approximately 65 million Americans and represents one of the largest single-payer programmes in the world within a predominantly private system. Its design — fee-for-service payment for most services, supplemented by private Medicare Advantage plans that now cover more than half of beneficiaries — embeds the same tension between provider incentives, cost control, and quality that runs through all health economics. Medicaid, jointly funded by federal and state governments and administered by states within federal minimum requirements, covers more than 80 million people and has been the subject of intensive natural experiment research enabled by the variation in programme design and eligibility across states and over time.
The Oregon Health Insurance Experiment and Medicaid’s Effect on Health Outcomes
Oregon’s randomised expansion of Medicaid eligibility via lottery produced one of the few genuine randomised experiments on the effects of health insurance on health outcomes — generating findings that were both important (insurance reduced financial stress and improved mental health) and provocative (effects on physical health outcomes were not statistically significant over the two-year observation window). The study’s design, findings, and limitations are a masterclass in health economics methodology.
Medicare Advantage: Favourable Selection, Quality, and Costs
The shift of Medicare beneficiaries from traditional fee-for-service to private Medicare Advantage plans raises fundamental questions about risk selection, quality comparisons, and the long-run fiscal implications of a programme that may attract healthier-than-average enrollees. Whether MA plans produce genuine efficiency gains or primarily engage in regulatory arbitrage is a live and consequential research question.
The Affordable Care Act’s Medicaid Expansion: State-Level Heterogeneity and Health Outcomes
The Supreme Court’s 2012 ruling made the ACA Medicaid expansion optional for states, producing natural variation across states and over time that researchers have used intensively to identify the expansion’s effects on coverage, utilisation, financial protection, and health outcomes — with implications for ongoing debates about full national expansion.
Hospital Price Transparency and Market Concentration in US Healthcare
The extraordinary variation in hospital prices for identical procedures — and the role of market consolidation in driving price inflation — represents one of the most active research areas in US health economics. The 2021 hospital price transparency rule offers new data for analysing price variation and the competitive dynamics of US hospital markets.
The Role of Administrative Costs in US Healthcare Inefficiency
Studies consistently find that US healthcare devotes 25–35% of spending to administrative costs — substantially more than comparable systems. Quantifying the sources of this excess (insurance complexity, billing heterogeneity, regulatory compliance) and evaluating the potential savings from administrative simplification is both empirically tractable and policy-relevant.
Value-Based Payment Reform in Medicare: Evidence on Alternative Payment Models
The Centers for Medicare & Medicaid Services (CMS) has piloted numerous alternative payment models — accountable care organisations, bundled payments, comprehensive primary care initiatives — intended to move from volume to value. The evidence on whether these models improve quality, reduce spending, or simply shift cost accounting provides a rich empirical research agenda for health economics students.
Using CMS Data for US Health Economics Research
The Centers for Medicare & Medicaid Services publishes an extraordinarily rich set of publicly available data resources — including Medicare claims data, quality reporting data, cost report data, and provider utilisation data — that support empirical research across a wide range of health economics topics. The CMS Research Data Assistance Center (ResDAC) facilitates researcher access to Medicare and Medicaid data through a formal application process. For graduate students and advanced undergraduates, these datasets offer the opportunity to produce original empirical work on some of the most consequential questions in US health policy. Our data analysis and statistics specialists can assist with the econometric and statistical methods required to work with these datasets effectively.
Universal Health Coverage — The Global Policy Agenda and Its Economic Foundations
Universal health coverage (UHC) — the goal that all people receive the health services they need without suffering financial hardship — is the organising principle of global health financing policy, enshrined in Sustainable Development Goal 3.8 and pursued by the World Health Organization as the central objective of health system development. For health economics researchers, UHC is both a normative framework (articulating what health systems ought to achieve) and an empirical research programme (generating evidence on how different financing arrangements, service delivery models, and benefit package designs advance or impede its achievement across diverse country contexts).
The economic foundations of UHC rest on several theoretical pillars. Health insurance — whether public or private, mandatory or voluntary — is theoretically justified by the combination of the high and unpredictable cost of serious illness, the risk aversion of most individuals regarding health expenditure, and the positive externalities of a healthy population. Prepayment and pooling are more efficient than out-of-pocket payment for these reasons — they spread risk, prevent catastrophic expenditure, and allow the healthy to cross-subsidise the sick. But the design of the pooling mechanism matters enormously: voluntary private insurance markets are prone to adverse selection and may leave the sickest and poorest unprotected; mandatory social health insurance may segment risk pools along employment lines, excluding informal sector workers; and tax-funded systems must navigate the political economy of public finance and competing claims on the revenue base. Understanding how different countries have navigated these trade-offs — and what the evidence on outcomes, equity, and sustainability suggests — is the central intellectual project of comparative health systems research.
Community-Based Health Insurance in Sub-Saharan Africa
Rwanda’s Mutuelle de Santé has become one of the most studied community-based health insurance programmes in the world, with evidence suggesting substantial gains in coverage, utilisation, and financial protection. But its generalisability to other African contexts — with different institutional capacity, community solidarity, and fiscal environments — is a rich comparative research question with direct policy implications.
Benefit Package Design and Priority Setting in Low-Income Countries
Every UHC system must decide which services to cover — a priority-setting problem that requires explicit or implicit choices about relative value, equity, and fiscal constraint. Research on how low-income countries design essential health benefit packages, how they use economic evidence in those decisions, and what the consequences are for service utilisation and health outcomes connects health economics to political economy and ethics.
Out-of-Pocket Expenditure and Catastrophic Health Spending
The WHO defines catastrophic health expenditure as out-of-pocket health costs exceeding 10% of household consumption. Research on the determinants of catastrophic spending — and the effectiveness of UHC expansions in reducing it — uses household survey data from the World Health Survey and national living standards surveys.
Thailand’s Universal Coverage Scheme
Thailand achieved near-universal coverage through a combination of civil servant medical benefit schemes, social health insurance for formal sector workers, and a universal coverage scheme for the remainder. It is widely cited as a model for middle-income countries, with a rich evidence base on implementation challenges, financing sustainability, and health outcomes.
UHC and Health System Resilience Post-COVID-19
The COVID-19 pandemic exposed significant differences in the resilience of health systems with different financing and delivery architectures. Research examining how UHC coverage levels, financing mechanisms, and health system capacity predicted pandemic preparedness and response quality is a consequential emerging literature.
A particularly productive research area within UHC is the political economy of health financing reform — why some countries succeed in transitioning from fragmented, out-of-pocket-dominated systems to effective UHC while others with similar economic starting points do not. The economic literature on this question draws on historical institutionalism, fiscal federalism theory, and the political economy of redistribution to identify the conditions under which reform coalitions can overcome the interests of those who benefit from existing arrangements — private insurers, pharmaceutical companies, provider associations, and wealthier segments of the population who value exit options over universal systems. This is a research area where health economics intersects productively with political science and sociology, and where comparative case study methods are as valuable as econometric analysis. For students writing at this intersection, our political science assignment help and sociology assignment help specialists offer cross-disciplinary support.
Pharmaceutical Pricing, Access, and Innovation — Economics at the Drug Pricing Frontier
The economics of pharmaceuticals sits at one of the most contested intersections in all of health policy — between the imperatives of innovation (which requires expected profits sufficient to recoup substantial R&D investment) and the imperatives of access (which requires prices low enough for all patients who need a medicine to receive it). This tension is not incidental but structural: the intellectual property system that grants pharmaceutical companies temporary monopoly pricing power is the deliberate mechanism by which innovation incentives are created, and the consequence is that the prices needed to incentivise innovation are higher than marginal production cost — sometimes dramatically so — creating access barriers that are particularly severe in lower-income countries and for patients without comprehensive insurance.
The economics of pharmaceutical pricing has become one of the most practically consequential research areas in health economics, driven by the approval of transformative but extraordinarily expensive therapies — cell and gene therapies, targeted oncology drugs, and biologics for immune-mediated conditions — whose list prices can reach hundreds of thousands or millions of pounds or dollars per patient. Understanding how prices are set, how they relate to the underlying costs of development and production, how different regulatory and negotiation frameworks affect both prices and access, and what alternative mechanisms might better balance innovation and access incentives is a research agenda with direct implications for health system budgets, patient outcomes, and global health equity.
| Research Topic | Key Question | Relevant System | Methodological Approach |
|---|---|---|---|
| Reference Pricing and Drug Affordability | Does international reference pricing — setting national reimbursement prices by reference to a basket of other countries’ prices — improve affordability without deterring innovation? | EU, UK, Canada | Comparative policy analysis; econometric modelling of launch timing and availability |
| NICE Appraisal and Access Delays | How long do patients in England wait between regulatory approval and NICE-recommended reimbursement — and how does this compare with European counterparts? What are the economic and clinical consequences of delayed access? | NHS England, NICE | Survival analysis; international comparisons; cost of delay modelling |
| Biosimilar Entry and Price Competition | When biologic patents expire and biosimilar competitors enter, do prices fall to competitive levels? What policy interventions — substitution policies, tendering, prescribing incentives — most effectively drive biosimilar uptake? | UK, US, EU | Market entry analysis; natural experiments using biosimilar launch dates |
| Orphan Drug Pricing and Rare Disease Policy | Orphan drug designations grant extended market exclusivity and reduced regulatory requirements to incentivise medicines for rare diseases — but have generated some of the highest prices in the pharmaceutical market. How should the trade-off between access and innovation incentives be redesigned? | EMA, FDA, NICE | Policy analysis; health technology assessment; multi-criteria decision analysis |
| Pharmaceutical R&D Productivity and Public Funding | A substantial share of the basic science underlying pharmaceutical innovation is publicly funded through NIH, MRC, and Wellcome Trust grants. How should this public investment affect the pricing of medicines developed on that scientific foundation? | US, UK, Global | R&D cost analysis; patent citation analysis; normative economic analysis |
| Generic Drug Market Failures and Shortages | Generic medicines — which should be cheaply available given competitive markets — have increasingly experienced shortages and price spikes due to market concentration, production fragility, and inadequate incentives for quality manufacturing. What are the economic causes and policy solutions? | US, UK, Global | Industrial organisation; supply chain analysis; regulatory economics |
Data Challenges in Pharmaceutical Economics Research
One of the most significant methodological challenges in pharmaceutical economics is the opacity of actual transaction prices. List prices published by manufacturers and approved prices used in NICE submissions or official price registers often bear little relationship to the confidential discounted prices negotiated between manufacturers and payers — particularly in the UK, where NHS commercial agreements for high-cost medicines are routinely confidential. This creates a systematic data gap that affects the reliability of international price comparisons and the analysis of affordability. Students researching pharmaceutical pricing should be explicit about this limitation and engage with the methodological literature on how researchers have attempted to work around it, including through the use of IQVIA commercial datasets, Freedom of Information requests, and cross-national patient access data as proxies. Our research paper specialists can help you design and write around these data constraints effectively.
Health Inequalities and Equity — The Social Determinants and Their Economic Dimensions
Health inequalities — the systematic differences in health status, healthcare access, and health outcomes across social groups defined by income, ethnicity, geography, gender, or other dimensions of social position — are among the most extensively documented and morally troubling facts in public health and health economics. The evidence is consistent and global: people with lower incomes live shorter, less healthy lives; ethnic minority populations experience worse health outcomes in most high-income countries even after controlling for socioeconomic factors; people living in deprived areas have higher rates of preventable illness and premature death; women experience systematic differences in the investigation and treatment of conditions whose presentation differs from the male norm that has historically dominated clinical research.
For health economics researchers, inequalities are interesting both as outcomes to be explained and as evidence about the operation of health systems and broader social arrangements. The Marmot Reviews — the 2010 Fair Society, Healthy Lives report and its 2020 ten-year follow-up — documented not only the persistence but the widening of health inequalities in England during the austerity decade, connecting these trends explicitly to cuts in public expenditure on social determinants including housing, early years provision, education, and social care. The economic analysis of these relationships — demonstrating that investing in the conditions of early life, in employment quality, in housing adequacy, and in community infrastructure generates health returns that partially or fully justify the investment in strictly economic terms — is one of the most practically consequential areas of health economics research.
Area Deprivation and NHS Resource Allocation
The NHS resource allocation formula attempts to direct funding toward more deprived areas with greater health need. Research examining whether the formula succeeds in this aim — and whether it adequately captures the greater cost of providing equivalent care in more deprived populations — connects allocation theory to the real-world measurement of need and cost.
The Ethnicity Health Gap in the United Kingdom
UK ethnic minority populations experience a complex pattern of health inequalities — with some groups experiencing excess mortality from specific conditions (cardiovascular disease in South Asian communities, mental health crises in Black communities) and others apparently experiencing better outcomes than comparable white British groups (the “healthy migrant” effect). Unpacking these patterns requires careful attention to data quality, confounding, and the specific mechanisms driving each inequality.
Socioeconomic Inequalities in Cancer Outcomes
Despite universal access to cancer diagnosis and treatment through the NHS, socioeconomic gradients in cancer survival persist for most major cancers. Research unpacking whether these reflect differences in stage at diagnosis, treatment received, or other factors — and what interventions might reduce them — is a priority for both academic research and NHS Cancer Programme.
Measuring Health Inequalities — Methods and Metrics
The measurement of health inequalities is itself a methodological research area, since different measures emphasise different dimensions of inequality and can produce different policy implications from the same underlying data. The concentration index — a summary measure of the socioeconomic distribution of health analogous to the Gini coefficient for income — is the most widely used measure in comparative research, with values ranging from -1 (all ill-health concentrated in the poorest) to +1 (all ill-health concentrated in the richest). The slope index of inequality and relative index of inequality are regression-based measures that use the full socioeconomic distribution rather than summary groupings, making them more statistically efficient. Decomposition methods — pioneered by Wagstaff, van Doorslaer, and Watanabe — allow researchers to attribute observed inequalities to specific determinants, facilitating the identification of the most important drivers and the most effective policy levers.
A growing area is the economics of health equity interventions — rigorous evaluation of policies specifically designed to reduce health inequalities rather than improve average health outcomes. The Inverse Care Law, first articulated by Julian Tudor Hart in 1971, observed that healthcare availability is inversely related to the need of the population served — a pattern that economic analysis can help explain (through demand-side and supply-side mechanisms) and that policy design can attempt to correct. Research on what works in this domain — which payment system designs, commissioning incentives, or social prescribing interventions are most effective at reaching and improving the health of the most deprived — is a high-priority area for NHS research and for academic health economics. For student support across health inequality topics, our public health assignment help and statistics assignment help teams are available for quantitative methods support. The Institute of Health Equity, led by Sir Michael Marmot, publishes comprehensive reports and briefings that provide essential background for any research in this area.
Mental Health Economics — The Neglected Dimension of Health System Value
Mental health conditions account for approximately 23% of the total burden of disease in England but receive only around 11% of NHS spending — a disparity that has been described as the “investment gap” and that represents one of the most consequential failures of resource allocation in the health system. For health economics researchers, mental health is an area of extraordinary opportunity: the evidence base for the cost-effectiveness of mental health interventions has grown substantially over the past two decades, the economic case for investment in mental health has been articulated with increasing precision, and the policy environment — driven by the NHS Long Term Plan’s mental health ambitions — is more receptive to this evidence than at any previous point.
The economic argument for investing in mental health rests on several pillars that together constitute what Layard and others have called the “return on investment” case for mental health care. Mental illness imposes substantial costs outside the health system — through reduced employment and productivity, welfare benefit receipt, criminal justice involvement, and educational underachievement. Effective treatment for conditions like depression and anxiety disorders — particularly Improving Access to Psychological Therapies (IAPT), now renamed NHS Talking Therapies — has been shown to reduce these wider economic costs in ways that may offset the full cost of treatment. Early intervention in psychosis programmes that prevent the accumulation of disability have even more striking economic cases. And the prevention of mental illness — through investment in early years mental health, school-based programmes, and addressing the social determinants of mental distress — has potential economic returns that dwarf the cost of intervention.
The Economics of IAPT / NHS Talking Therapies
The NHS Talking Therapies programme is the largest government-funded psychological therapy programme in the world, treating over a million people per year. Research questions include its cost-effectiveness relative to pharmacotherapy, its equity of access across demographic groups, the consequences of recent changes to workforce composition and session limits, and whether its outcomes justify continued expansion relative to competing mental health priorities.
Economic Consequences of Mental Health in Employment
Mental illness is the leading cause of long-term sickness absence and a major driver of disability benefit claims in the UK. Research on the employment effects of different mental health treatment approaches — and on workplace mental health interventions — is important both for health economics and for labour economics. The fit notes data and the benefits administrative records available through HMRC linkage offer rich empirical opportunities.
Child and Adolescent Mental Health Economics
Investment in child and adolescent mental health services (CAMHS) is often justified through its long-run economic returns — preventing the accumulation of adult mental health problems, reducing educational disruption, and enabling better labour market outcomes. Research on the cost-effectiveness of CAMHS interventions, and the economics of early identification in school settings, connects mental health economics to education economics and developmental economics.
Measuring the Value of Mental Health Outcomes
The QALY framework used in physical health economic evaluation sits awkwardly with mental health — the EQ-5D measure used to generate QALY estimates is poorly responsive to change in mental health conditions, and the generic preference weights underlying it may not reflect the values of people with mental illness. Research on measurement alternatives — including the WEMWBS and specific measures like the ICECAP-A — is a live methodological debate with direct implications for NICE appraisals.
Key Datasets for Mental Health Economics Research in the UK
Several key administrative and clinical datasets support mental health economics research in England. The Mental Health Services Dataset (MHSDS) covers all NHS-funded secondary mental health, learning disability, and autism services. The NHS Talking Therapies outcomes dataset provides session-by-session clinical outcomes for the psychological therapies programme with sociodemographic data supporting equity analysis. The CPRD (Clinical Practice Research Datalink) provides longitudinal GP data with mental health recording that supports research on primary care management and treatment pathways. For students using these datasets, our data analysis and statistics help team can provide support with the specific econometric and statistical methods required for health administrative data research.
Long-Term Care, Ageing Populations, and Fiscal Sustainability
The economics of long-term care — the support provided to people with enduring care needs arising from age, disability, or chronic illness — is one of the most pressing and least resolved areas in health and social policy across all high-income countries. The fiscal pressure is clear: population ageing is increasing the number of people with age-related care needs at precisely the moment when the ratio of working-age to retirement-age population is declining, compressing the tax base from which publicly funded care would need to be financed. But the political and ethical dimensions are equally challenging: long-term care needs are highly unequally distributed across the population (a small minority require very expensive care while most need relatively little), they interact with wealth and housing assets in ways that make means-testing politically toxic, and they have historically fallen between the NHS (free at the point of use) and social care (means-tested and funded by local authorities) in ways that create perverse incentives, care gaps, and deep inequities.
In England, the Dilnot Commission (2011) proposed a cap on individual lifetime social care costs — eventually implemented in modified form from 2025 — as a mechanism to protect individuals against catastrophic care costs while maintaining means-testing below the cap. The economics of this design, its distributional consequences, its fiscal implications, and its likely effects on informal care provision, housing equity release, and insurance market development are all important research questions. Comparatively, Germany’s long-standing social care insurance system, Japan’s long-term care insurance scheme (established in 2000), and the Nordic countries’ tax-funded approaches offer a range of institutional models against which England’s hybrid approach can be assessed.
The Economics of Informal Care and the Hidden Care Economy
The majority of care for people with long-term needs is provided by unpaid family members — at an estimated economic cost (in lost employment, leisure, and health) of around £132 billion per year in England. Research on the labour market consequences of caregiving, the substitutability of informal and formal care, and the distributional effects of policies that depend heavily on unpaid care provision is both analytically important and policy-urgent.
Dementia Economics: Costs, Care Pathways, and Intervention Value
Dementia is the most expensive condition in England’s health and care system — with estimated annual costs of around £25 billion — yet the economic evaluation of dementia interventions has been hampered by challenges in QALY measurement (including for proxy respondents), long time horizons, and substantial informal care costs. The development of disease-modifying treatments creates urgent need for economic models that can evaluate their value given these complexities.
Care Home Markets: Quality, Competition, and Regulation
The English care home market is predominantly private — a legacy of 1980s deinstitutionalisation policy — creating a complex market with significant quality variation, thin margins, and recurrent provider failures. Economic research on market structure, quality competition, and the role of regulation in addressing information asymmetries between residents, families, and providers is a productive area.
Healthy Ageing and Preventive Investment
Compression of morbidity — the reduction of the period of ill health at end of life through investment in healthy ageing — has potential economic implications that go well beyond health: reducing care needs, extending working lives, and improving quality of life in ways that have broad welfare value. Research on the cost-effectiveness of healthy ageing interventions connects prevention economics to the wider economics of ageing.
End-of-Life Care Economics
Healthcare costs are disproportionately concentrated in the final months of life. Research on the economics of end-of-life care — including the value of different care settings (hospice versus hospital), the cost-effectiveness of palliative care interventions, and the economics of advance care planning — raises important questions about how economic evaluation frameworks handle the measurement of value near death.
Cost-Effectiveness Analysis and Health Technology Assessment — The Valuation of Health
Cost-effectiveness analysis (CEA) and health technology assessment (HTA) are the methodological engines that convert health economics research into health policy decisions — the analytical frameworks through which the question “is this intervention worth funding?” is given a structured, evidence-based answer. They sit at the intersection of economics (measuring costs), epidemiology (measuring effects), decision science (handling uncertainty), and ethics (making value judgements about what counts as a benefit), and they represent one of the most technically demanding and practically consequential areas of applied health economics research.
In England, the National Institute for Health and Care Excellence (NICE) is the primary HTA body, conducting technology appraisals that recommend for or against NHS reimbursement of medicines, devices, and procedures. The core of a NICE technology appraisal is a cost-effectiveness model that estimates the incremental cost per QALY gained by the new technology relative to existing standard of care, comparing this against a cost-effectiveness threshold of £20,000–30,000 per QALY (with end-of-life exceptions allowing up to £50,000). Understanding how these models are constructed, what assumptions drive their results, and what the limitations of the QALY framework are is essential knowledge for health economics researchers working on any aspect of healthcare decision-making.
Most cost-effectiveness models for chronic conditions use a Markov structure — a set of health states (e.g., stable disease, progression, death) between which patients transition at rates estimated from clinical trial or real-world data. The choice of states, the time horizon, the cycle length, and the discount rate (currently 3.5% per year for both costs and effects in NICE’s reference case) all affect the model results and require justification. Simpler decision tree structures are used for acute conditions where time does not affect outcomes differentially.
The model populates these structures with clinical inputs (transition probabilities, treatment effect sizes) from clinical trials and meta-analyses, utility weights (QALY multipliers for each health state) from preference elicitation studies using instruments like EQ-5D, resource use data from clinical trials or NHS administrative databases, and unit cost data from NHS reference costs and Personal Social Services Research Unit cost databases. The interaction between these inputs determines the cost-effectiveness estimate.
Probabilistic sensitivity analysis (PSA) — running the model thousands of times with parameter values sampled from probability distributions — generates a cost-effectiveness acceptability curve showing the probability that the technology is cost-effective at different willingness-to-pay thresholds. Deterministic sensitivity analysis identifies which parameters the model results are most sensitive to. Understanding this uncertainty framework is essential for interpreting cost-effectiveness results and for research that seeks to improve on existing models.
Common research topics in this area include evaluating the cost-effectiveness of a specific intervention using an existing model structure with updated data, comparing alternative model structures and their implications for decisions, methodological research on QALY measurement in specific patient populations, threshold analysis examining the conditions under which a technology becomes cost-effective, and equity-weighted cost-effectiveness analysis that applies additional weight to health gains in disadvantaged populations.
Critiques and Alternatives to the QALY Framework
The QALY is the dominant currency of health economic evaluation but not an uncontested one. Several critiques have generated productive research agendas. The disability rights critique argues that QALYs systematically discriminate against people with disabilities by assigning lower quality-of-life weights to health states that disabled people themselves may not rate as severely as non-disabled evaluators — leading to cost-effectiveness conclusions that give less weight to the health of disabled people. The fair innings argument suggests that health gains should be weighted by age — prioritising those who have had least opportunity to live a healthy life — in ways that standard QALY maximisation does not. The severity weighting approach, incorporated into NICE’s severity modifier introduced in 2022, attempts to give additional weight to health gains for the most severely ill. And the capability approach associated with Amartya Sen proposes that the relevant metric for health policy is not health-related quality of life but the broader freedom to live a life one values — a framework operationalised in health economics through the ICECAP capability measures. Each of these critiques and alternatives generates distinct research questions, and engaging with them is a mark of methodological sophistication in health economics dissertation work. For support with advanced health economics methodology, our statistics assignment specialists and dissertation writing service provide specialist guidance.
Research Methods in Health Economics — Causal Inference, Data, and Design
Health economics is a deeply empirical discipline — its claims about how healthcare markets work, what health system designs produce better outcomes, and whether specific interventions are cost-effective rest on careful analysis of data from clinical trials, observational studies, administrative records, and surveys. The methodological standards of the field are high and growing more demanding: the credibility revolution in applied microeconomics — the shift toward research designs that can credibly claim to identify causal effects rather than mere correlations — has transformed health economics alongside the rest of empirical economics. For students designing health economics research projects, understanding the causal inference toolkit and its applications in health and health policy research is as important as understanding the substantive research questions themselves.
| Method | What It Identifies | Key Applications in Health Economics | Main Limitation |
|---|---|---|---|
| Randomised Controlled Trial (RCT) | Average treatment effect under randomisation — the gold standard for causal identification | Clinical effectiveness trials; health insurance experiment (RAND, Oregon); evaluations of public health interventions | Internal validity may not generalise; ethical constraints on randomisation; expensive and slow; cannot address many system-level questions |
| Regression Discontinuity Design (RDD) | Local average treatment effect for observations near an eligibility threshold | Effects of Medicare eligibility at age 65 (Card, Dobkin, Maestas); effects of benefit eligibility thresholds; NICE threshold analysis | Local estimate only — may not generalise far from the threshold; requires precise measurement of the running variable |
| Instrumental Variables (IV) | Causal effect of a treatment variable using an instrument that affects treatment but not outcomes directly | Effects of hospital competition using geographic instruments; effects of surgical volume on outcomes using distance as instrument; effects of insurance on healthcare use | Requires valid instrument — exclusion restriction is often untestable and controversial; local average treatment effect may not be the policy-relevant parameter |
| Difference-in-Differences (DiD) | Causal effect of a policy or programme using pre-post comparison between treated and untreated groups | Effects of Medicaid expansion (comparing expansion vs. non-expansion states); effects of NHS reforms; effects of public health policies | Requires parallel trends assumption — that treated and untreated groups would have followed the same trend absent treatment |
| Synthetic Control Method | Causal effect of a policy using a weighted combination of untreated units as the counterfactual | Effects of state-level health policy changes when only one or a few states are treated; tobacco control policy evaluations | Requires a good pre-treatment fit between treated unit and synthetic control; limited to cases with many potential control units |
| Cost-Effectiveness Modelling | Decision-analytic synthesis of evidence on costs and effects to inform reimbursement decisions | NICE technology appraisals; economic evaluation alongside clinical trials; budget impact analysis | Model structure and parameter uncertainty may be large; extrapolation beyond trial evidence requires assumptions that may not be testable |
Key Data Sources for Health Economics Research
The quality of health economics research depends critically on the quality and appropriateness of the data used. Students selecting a research topic should give serious attention to what data are actually available — both to ensure the project is feasible and to identify the methodological approach the data structure can support. Several major data sources deserve specific attention for UK and international health economics research.
UK Data Sources
- NHS Digital Hospital Episode Statistics (HES) — all NHS hospital admissions
- Clinical Practice Research Datalink (CPRD) — GP records for ~15% of UK population
- NHS Business Services Authority (NHSBSA) — prescribing and dispensing data
- NHS Outcomes Framework — system-level performance indicators
- Understanding Society — longitudinal household panel with health modules
- Health Survey for England — annual population health survey with biomarkers
- ONS Longitudinal Study — 1% sample linked to census, vital events, cancer registry
- NHS England Integrated Care Board spending data
US & International Data Sources
- Medicare and Medicaid claims data (via CMS ResDAC)
- Medical Expenditure Panel Survey (MEPS)
- National Health Interview Survey (NHIS)
- WHO Global Health Observatory — comparative international data
- OECD Health Statistics — standardised comparisons across OECD countries
- World Bank Health Nutrition and Population dataset
- Demographic and Health Surveys (DHS) — low/middle-income country data
- Global Burden of Disease study data (IHME)
Checklist for a Strong Health Economics Research Proposal
- Research question is specific, policy-relevant, and has a clear economic dimension
- The causal identification strategy is clearly articulated — how will you establish causality, not just correlation?
- Data source is identified and access is feasible within the project timeline
- Theoretical framework connects the research question to established economic theory
- Literature review covers both foundational theoretical papers and recent empirical work in the area
- Methodological approach is appropriate to the data structure and research question
- Limitations of the method are explicitly acknowledged and their implications assessed
- Ethical considerations — data privacy, consent, IRB/ethics committee approval — are addressed
- Potential policy implications of the findings are articulated
- The contribution to existing knowledge is clearly stated — what gap does this study fill?
For students working with large administrative datasets, the technical demands — data management, econometric programming in Stata or R, handling of missing data, clustering of standard errors — can be substantial. Our statistics assignment help and data analysis specialists provide hands-on support with these technical dimensions of health economics research. For the broader literature review and writing dimensions of research projects, our literature review writing and dissertation writing service teams offer comprehensive guidance. The National Bureau of Economic Research Health Economics programme publishes working papers from the world’s leading health economists that represent the current frontier of empirical research — an invaluable resource for identifying the most important current questions and methodological approaches in the field.
FAQs: Health Economics Research Topics — Your Questions Answered
Conclusion: Why Health Economics Research Matters Now More Than Ever
Health economics sits at the intersection of the most urgent practical challenges and some of the deepest intellectual questions available to a researcher. How do you value health? How should scarce resources be distributed across a population with competing health needs? What institutional arrangements produce the most efficient and equitable healthcare? How do you design systems that harness market mechanisms without suffering their characteristic failures? These questions have no neat answers — they require the careful combination of economic theory, empirical evidence, ethical reasoning, and institutional analysis that the best health economics research exemplifies.
The research areas covered in this guide — NHS funding and reform, Medicare and Medicaid policy, universal health coverage, pharmaceutical pricing, health inequalities, mental health economics, long-term care, cost-effectiveness analysis, and research methods — are not isolated topics. They are interconnected dimensions of a single question: how do societies organise the production and distribution of health? Understanding how the NHS’s funding gap connects to its workforce crisis, how pharmaceutical pricing decisions connect to global health equity, how mental health investment connects to labour market productivity, how the measurement of health connects to decisions about whose health counts — these connections are what transform a collection of research topics into a field with a coherent intellectual project.
For expert support at every stage of your health economics research — from initial topic selection through literature review, research design, data analysis, writing, and final editing — the specialists at Smart Academic Writing are ready to help. Explore our research paper writing services, our dissertation writing support, our economics homework help, and our editing and proofreading service. Get started through our write my research paper page or contact us through our contact page. Review our FAQ for answers to common questions, or check our pricing page to understand our transparent service model.